Market Research Hub

Global Respiratory Drugs Market Prospects, Trends and Forecast Outlook Until 2023

The leading companies in terms of market share are GSK, AstraZeneca and Boehringer Ingelheim.


Albany, NY -- (SBWIRE) -- 10/10/2017 -- Market Research Hub (MRH) introduces a new research report to its offerings that focus on the global market for respiratory drugs. This report titled "Global Respiratory Drugs Market to 2023" focuses on the key therapy area indications of asthma, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). The readers are informed about the global revenue from the respiratory market along with the forecasted status for the period until 2023.

Request a Sample Report :

The respiratory therapy area consists of signals that affect the respiratory system in different ways, such as the scarring of lung tissue, inflammation and excessive production of mucus in the airways. Furthermore, the causes of respiratory disorders vary significantly through each indication and comprise of factors such as environment, genetic predisposition, occupation, and aging. Presently, 937 products are being actively settled in the respiratory pipeline. Furthermore, the pipeline for asthma, IPF, COPD, and CF contain 261, 79, 106 and 131 products, respectively. The traditional non-specific symptomatic therapies have a strong presence in the respiratory disorder pipeline, however, the pipeline also includes capable targeted biologic therapies.

The research report offers a crisp view of the current treatment landscape, with portfolios of main marketed products and a strong emphasis on historical and forecast sales patterns. This study focuses on the key marketed products such as Advair – GSK, Spiriva - Boehringer Ingelheim, Xolair - Roche/Novartis, Symbicort - AstraZeneca/Astellas Pulmicort - Astra Zeneca etc. It has been analyzed that, global revenue from the respiratory market is expected to increase from $30.9 billion in 2016 to $41.3 billion in 2023; this points out to an annual growth rate of 4.23%.

Browse Full Report with TOC-

Considering the growth factors for the advancement of the global respiratory drugs market, the approval of the products such as Kalydeco and Orkambi, in 2012 and 2014 respectively, offered patients disease-modifying treatment choices for CF. Moreover, targeted biologics have also emerged effectively, such as omalizumab and Nucala for treating asthma. Looking at the forecast analysis, the global market for respiratory drugs is studied on the basis of market size and revenue. The forecasts also provide an understanding of how new drug entries, epidemiology trends and patent expirations will impact the market value.

Overall, the research report highlights the commercial opportunities in the respiratory deals landscape through the analysis of active trends in licensing and co-development deals.

Enquire about this Report-

About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH's expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us
90 State Street,
Albany, NY 12207,
United States
Toll Free : 800-998-4852 (US-Canada)
Email :
Website :
Read Industry News at -